- Ramadan 2019 and fasting
- Warning! Be careful about completing your driving licence application online!
- If you shop on Amazon, here’s how you can help IDDT
- Medical Device Awareness Card Now Available
- DVLA Guidelines make it simpler for drivers with insulin treated diabetes
- A no deal Brexit could put lives at risk (updated)
- New Ulcer treatment could prevent 3,000 amputations a year
- FreeStyle Libre latest News!!!
- NHS Long-Term Plan
- FreeStyle Libre
- Pork insulin availability in the UK and Canada assured
- NHS to provide life changing glucose monitors for Type 1 Diabetes patients
- Leading experts slam current diabetes care in UK care homes – a Call to Action needed
- Roche announces urgent recall on certain Accu-Chek Aviva and Performa test strips
- Ramadan 2018 and fasting
- DVLA changes regulations
- Freestyle Libre available on the NHS!
- Medtronic recall specific lots of infusion sets with all models of Medtronic insulin pumps
- All Accu-Chek® Insight insulin pumps – risk of alarm failure
- WHO – long-acting analogues not an essential medicine
- Beef insulin discontinued
- Soft Drinks Warning!
- Driven to Despair
- 2017 – Getting back on track after Christmas
- Childhood Obesity Strategy failing our children
- Diabetes – What schools need to know
- DVLA – Good News!
- The National Diabetes Foot Care Audit (NDFA)
- Diabetes care criticised
- Motorists banned in error after faulty DVLA visual field test
- Too many children and young people with diabetes not getting the care they need
- National NHS Diabetes Prevention Programme
- InDependent Diabetes Trust: Young diabetics ‘get worse care’
- IDDT’s Position Statement – ‘pre-diabetes’
- MBE Is Bolt From The Blue For Charity Chair
- New insulin on the market – Insulin Degludec (Tresiba)
- Diabetes community urges more support for older people
- Warning to people with diabetes about dangerous herbal medicine
- In 1 week, 60 hospital patients with diabetes develop preventable complications – National Audit
- Passport for Diabetes in Care Settings
- Launch of Passport for Diabetes in Care Settings
- Type 2 Diabetes – Management & Medication
- Cost of insulin analogues
- Actos And The Risk Of Bladder Cancer – New Safety Warnings
- Actraphane – are patients really at the centre of care
- Marketing of insulin – a missed opportunity
- IDDT Launch Patient Hospital Passports
- IDDT Launch Public Awareness Campaign
- IDDT’s Position Statement on DTCA
- In Sickness and in Health
- IDDT Triumphs in Australia
Marketing of insulin – a missed opportunity
16th December 2010
The Insulin Dependent Diabetes Trust [IDDT] comments that the Channel 4 News item [15.12.10] successfully highlighted the huge waste of valuable NHS funds, tax payers’ money, on the prescribing of newer synthetic insulins which have no proven benefits for the vast majority of people needing insulin treatment. It did point out that if half of those taking analogue insulins had been prescribed so-called human insulin, £250 million could have been saved over the last 5 years – money which could have been spent on better care for patients, for example, by removing the restrictions on essential blood glucose test strips or employing more specialist nurses to provide more and better education for people with diabetes.
The programme missed a valuable opportunity to address some very key issues. IDDT would like to know how the pharmaceutical companies have managed to persuade the NHS, doctors and nurses to prescribe very costly analogue insulins that have no proven benefits for the vast majority of patients? NICE guidance quite clearly states that analogue insulins should not be the first choice of insulin, so why has NICE guidance been ignored by prescribers and PCTs, who are usually only too ready to restrict spending on glucose test strips and other drugs? It is insufficient to say that insulin analogues have been ‘oversold’. The public need to know what marketing techniques are employed to cause prescribers to ignore evidence from research and subsequently make prescribing decisions that are not necessarily in the best interests of patients, the NHS or the taxpayer?
But most importantly, the programme did not address the fact that the long-term safety and efficacy have not been proved for insulin analogues. For one long-acting insulin at least, the European Medicines Agency has stated that ‘they cannot deny or confirm’ that there is an increased risk of tumours developing and more research is needed. If health professionals provided their patients with the truly informed choice of insulins to which they are entitled, would they really choose analogue insulins?
Jenny Hirst, Co-Chair of IDDT commented, “We heard the insulin manufacturers telling us that analogue insulins are better. Many health professionals believe they are better despite the lack of evidence from research. However, this was not balanced by any discussions about risks and adverse reactions, nor was there a patient perspective. Ultimately patients are the consumers and can be the victims of drug company policies!”
She continued, “IDDT believes that Channel 4 missed a valuable opportunity to investigate many issues that are the key to good healthcare. It is not simply about cost but as NICE advises, it is about cost effectiveness. People with diabetes need individualised treatment to suit their needs and to provide the best quality of life. This means being given an informed choice of treatment, including information about risks and benefits and the long-term safety of the various types of insulin, synthetic human, analogue and natural animal insulin.”
For press enquiries please contact:
Direct: 01604 622837